78 results about "CCR8" patented technology

Provided is the development and use of a novel immunomodulator. The immunomodulator is an antibody or an antigen-binding portion thereof that binds to CCR8. The antibody has a neutralizing activity in blocking CCL1 / CCR8 axis, can inhibit CCL1-induced cell activation, and for low-affinity FcγRIIIA158F allele carriers in the population, enhances the ADCC effect by means of Fc optimization.

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

Provided herein are various embodiments relating to anti-CCR8 binding agents, that bind to CCR8, and uses thereof. Some of the embodiments include antibodies, fragments thereof, variants thereof, derivatives thereof, and binding polypeptides targeting the same that bind CCR8. Such anti-CCR8 binding agents can be used in methods to treat, for example, cancer.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist, particularly an insurmountable antagonist, of the CCL1-CCR8 signaling pathway. The invention also relates to the antibody or antigen-binding fragment for use in therapy, particularly in the treatment of cancer.

The present disclosure provides, inter alia, methods of treating locally advanced, recurrent or metastatic solid tumor malignancies in a subject by administering an anti-CCR8 antibody to the subject in need thereof, and related therapeutic uses.

Provided are a CCR8-targeting antibody or an antigen-binding fragment thereof, and an application thereof. The antibody targeting CCR8 or the antigen binding fragment of the antibody is specifically bound with CCR8. The invention further provides application of the antibody in blocking a signal channel for binding / inducing CCR1 and CCR8, clearing CCR8 positive Treg cells through ADCC action and enhancing anti-tumor immunity.

Provided are a multispecific antibody and the use thereof. Specifically, provided is a multispecific antibody, which contains a first targeting domain that targets a chemokine (C-C motif) receptor 8 (CCR8) molecule highly expressed on the surface of a tumor-infiltrating regulatory T cell (Treg), and a second targeting domain that binds to VEGF and / or a third targeting domain that binds to PD-L1. Various functional domains of the CCR8-related multispecific antibody block a PD-1 / PD-L1 immunosuppressive pathway, etc. by means of killing the tumor-infiltrating Treg, so that a T cell is activated, and the generation of a tumor vessel is inhibited. Therefore, the CCR8-related multispecific antibody can be used as an effective therapeutic agent for tumor treatment.

An anti-CCR8 antibody or antigen-binding fragment thereof. The anti-CCR8 antibody can recognize human CCR8 protein, block the signal pathway between CCR8 and CCL1 / CCL18, and recognize cells expressing CCR8, and also has target specific ADCC activity on target cells expressing CCR8.

This disclosure relates to a stable pharmaceutical formulation of an anti-human CCR8 monoclonal antibody and its use. The pharmaceutical formulation of the anti-human CCR8 antibody described herein is highly stable and can meet pharmaceutical use requirements even after long-term storage, high or low temperatures, freeze-thaw cycles, and shaking, and is expected to have a wide range of applications.

The present application relates to the technical field of biology, and discloses an anti-CCR8 antibody or an antigen binding fragment thereof, and a use thereof. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibilities for the treatment and / or prevention of cancer.

The invention relates to an anti-CCR8 monoclonal antibody and application thereof, in particular to an anti-CCR8 monoclonal antibody which can be combined with CCR8 derived from primates. The invention also relates to a pharmaceutical composition containing the anti-CCR8 monoclonal antibody, and an application of the anti-CCR8 monoclonal antibody and / or the pharmaceutical composition in prevention and / or treatment of tumors or cancers.

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

This disclosure provides antibodies that specifically bind to CCR8, antibody fragments, their antigen-binding portions, and their related applications. The anti-CCR8 antibody disclosed herein possesses the differentiated advantage of targeting CCR8 and has promising application prospects, enabling the provision of more drug options and treatment regimens for cancer patients.

The invention relates to the field of biological medicine, in particular to an antibody specifically binding to CCR8 or an antigen binding fragment of the antibody, and a pharmaceutical composition and a kit containing the antibody or the antigen binding fragment. The antibody or the antigen binding fragment thereof has ADCC activity and / or ADCP activity, and also has a good tumor inhibition effect. Therefore, the invention further relates to the use of the antibody or the antigen binding fragment thereof in the prevention and / or treatment of tumors.

The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human CCR8, a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer.

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

The present invention provides anti-CC motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The present invention also features polynucleotides, vectors, host cells, production methods, pharmaceutical compositions, methods for treating diseases or disorders such as cancer, methods for depleting regulatory T cells, compositions for related applications and uses, and kits for use in conjunction with one or more methods.

An antibody specifically binding to CCR8, an antibody fragment, an antigen-binding part thereof, and the related use. The anti-CCR8 antibody has a differentiation advantage of targeting CCR8, thereby providing a medication choice and therapeutic regimen for tumor patients.

The invention belongs to the field of biological medicine. Specifically, the invention provides an antibody targeting CCR8 and application of the antibody. More specifically, the invention provides an antibody targeting CCR8, STAR and CAR derived from the antibody, a therapeutic immune cell comprising the STAR or CAR, and applications thereof in disease treatment.

The invention discloses an anti-CCR8 antibody or an antigen binding fragment thereof and application thereof, and relates to the technical field of biology. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibility for treatment and / or prevention of cancers.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.

Provided is an antibody-drug conjugate represented by formula (1), or a pharmaceutically acceptable salt thereof. [wherein mAb represents an antibody that binds to CCR8, or a fragment thereof; n represents an integer from 1 to 8; L represents a group represented by formula (L-1), (L-2), (L-3) or (L-4); and Z represents a group represented by formula (Z-1), (Z-2) or (Z-3).]

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

The invention belongs to the technical field of molecular biology, and particularly relates to an anti-human CCR8 monoclonal antibody and a preparation method thereof. The anti-human CCR8 monoclonal antibody disclosed by the invention comprises VHCDR1, VHCDR2 and VHCDR3, wherein the amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are shown as SEQ ID NO: 1-3; the amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are as shown in SEQ ID NO: 4-6. The antibody development process comprises the following steps: synthesizing Human CCR8mRNA, immunizing a mouse, collecting spleen, bone marrow and lymph node cells of the mouse, wrapping a single plasma cell suspension, a fluorescence labeled secondary antibody and a Human CCR8HEK293 overexpression cell line in water-in-oil liquid drops together by adopting a microfluidic liquid drop sorting system, carrying out dielectrophoresis sorting, and enriching plasma cells secreting the target cell binding antibody; carrying out single-cell library construction on plasma cells, and carrying out NGS sequencing to obtain antibody sequences with naturally paired light and heavy chains; and selecting an antibody sequence for high-throughput expression of mammalian cells, and carrying out flow detection verification. The monoclonal antibody provided by the invention has good antigen-antibody binding activity and specificity on the cellular level.

Provided are antibodies and antigen-binding fragments thereof that bind to human CCR8, pharmaceutical compositions comprising said antibodies, and the use of the antibodies or the compositions for the treatment of diseases, such as cancer.

The present invention provides an antibody or antigen-binding fragment thereof that specifically binds to human CCR8. The present invention also provides a polynucleotide encoding the antibody or antigen-binding fragment thereof, a vector comprising the polynucleotide, a host cell comprising the vector, a method for generating the antibody, and a composition comprising the antibody.

To provide antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same.SOLUTION: Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof. Certain aspects of the present disclosure are directed to antibodies or antigen-binding portions thereof that specifically bind one or more amino acids within the N-terminal extracellular domain of human CCR8.SELECTED DRAWING: None